Zevalin

Zevalin (ibritumomab tiuxetan) is a targeted radiotherapeutic agent used for certain types of non-Hodgkin lymphoma. This prescription medication combines immunotherapy with radioisotope delivery for precision treatment. Suitable for patients unresponsive to other therapies, it is administered under medical supervision. Seek professional guidance for suitability and dosing.

Zevalin (ibritumomab tiuxetan) is primarily used to treat relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma, including follicular lymphoma. It may be prescribed when other treatments have not been effective. The drug targets cancer cells while sparing healthy tissue, making it a specialized option. Patients often explore this therapy after standard treatments fail.

As a radiopharmaceutical, Zevalin delivers targeted radiation to cancer cells, which may help reduce tumor size and slow disease progression. Common effects include mild fatigue or nausea during treatment, though these vary by individual. Some patients report temporary changes in blood cell counts due to bone marrow impact. Effects are typically monitored closely by healthcare providers.

Zevalin requires careful handling due to its radioactive properties; it is administered in controlled clinical settings by trained professionals. Patients should disclose full medical history, especially blood disorders or infections, before treatment. Regular blood tests are necessary to monitor safety and response. Avoid close contact with pregnant women or young children post-treatment as directed.

Zevalin may interact with other medications affecting bone marrow or immune function, such as chemotherapy or immunosuppressants. Live vaccines should be avoided during and after treatment due to reduced immune response. Blood thinners or drugs impacting blood cell production may require adjustment. Always inform your healthcare provider about all medications and supplements.